
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
What are the genetic and acquired risk factors for thrombosis? How is it treated, and what follow-up is required? Two experts offer some answers&151;and call for additional research.






